Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

AstraZeneca : European Medicines Agency Recommends Asthma Treatment Approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 01:23pm CEST

By Adam Clark

AstraZeneca PLC (AZN.LN) said Friday that the European Medicines Agency has recommended the marketing authorization of its benralizumab drug for asthma treatment.

The pharmaceutical company said the recommendation is based on phase 3 clinical trial data and is an important step towards providing a next-generation treatment for severe, uncontrolled asthma patients.

The positive opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The drug is also under regulatory review in the U.S., Japan and several other countries.

Shares are down 54 pence, or 1.1%, at 4908 pence at 1203 GMT.

Write to Adam Clark at [email protected]; @AdamDowJones

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
07/18ASTRAZENECA : Increases Drug Stockpile in Preparation for Hard Brexit
DJ
07/18ASTRAZENECA : to stockpile drugs as Brexit 'safety net'
RE
07/18ASTRAZENECA : 10.1% Potential Upside Indicated by Deutsche Bank
AQ
07/18Fetal gene therapy could treat neurodegenerative disease
AQ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
07/16ADVAXIS : rises after FDA lifts clinical hold
AQ
07/12ASTRAZENECA : FARXIGA in Combination with ONGLYZA Demonstrates Similar Glycemic ..
AQ
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
DJ
07/06HITTING CANCER EARLY : AstraZeneca's bid to outmaneuver rivals
RE
07/06New synthetic lethal interactions with PARP inhibition
AQ
More news
News from SeekingAlpha
11:10aBig Pharma in the red on ramped up pressure on drug prices 
07/18FDA committed to easing approval path for biosimilars 
07/18AstraZeneca to stockpile drugs ahead of Brexit 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
Financials ($)
Sales 2018 22 201 M
EBIT 2018 5 245 M
Net income 2018 1 969 M
Debt 2018 14 506 M
Yield 2018 3,72%
P/E ratio 2018 39,28
P/E ratio 2019 31,67
EV / Sales 2018 4,84x
EV / Sales 2019 4,57x
Capitalization 93 044 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 74,8 $
Spread / Average Target 2,1%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.47%93 044
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225